	US 12,404,279 B2
	Deubiquitinase inhibitors and methods of use thereof
Jacek Chrzanowski, Łódź (PL); Julita Nowicka, Wola Grzymkowa (PL); Łukasz Joachimiak, Lodz (PL); Robert Koralewski, Lodz (PL); Sylwia Olejniczak, Lodz (PL); Marzena Mazur, Lodz (PL); Bartlomiej Borek, Lodz (PL); Anna Gzik, Wartkowice (PL); Krzysztof Matyszewski, Lodz (PL); Sylwia Ciastek-Iskrzycka, Łódź (PL); Piotr Niedziejko, Warsaw (PL); Angelika Muchowicz, Warsaw (PL); Zbigniew Zasłona, Warsaw (PL); Roman Błaszczyk, Lodz (PL); Jacek Olczak, Łódź (PL); and Adam Golebiowski, Madison, CT (US)
Assigned to Molecure S.A., Warsaw (PL)
Filed by Molecure S.A., Warsaw (PL)
Filed on Dec. 22, 2022, as Appl. No. 18/145,618.
Claims priority of provisional application 63/296,570, filed on Jan. 5, 2022.
Claims priority of provisional application 63/293,205, filed on Dec. 23, 2021.
Prior Publication US 2023/0219973 A1, Jul. 13, 2023
Int. Cl. C07D 495/04 (2006.01); A61P 35/00 (2006.01); C07D 471/04 (2006.01); C07D 491/048 (2006.01); C07D 513/04 (2006.01); C07D 519/00 (2006.01)

CPC C07D 495/04 (2013.01) [A61P 35/00 (2018.01); C07D 471/04 (2013.01); C07D 491/048 (2013.01); C07D 513/04 (2013.01); C07D 519/00 (2013.01); C07B 2200/07 (2013.01)]

5 Claims

1. A compound of structural Formula (Ia):

wherein:

R²is selected from hydrogen, methyl, ethyl, chloro, —C≡N, and —CF₃;

L³represents a single bond, —CH₂—, —C(═O)—, —NH—, or —NH—C(═O)—; and

R³is selected from (4-6) membered heterocycloalkyl containing 1 to 2 nitrogen heteroatoms or 1 nitrogen heteroatom and 1 oxygen heteroatom, and optionally substituted with 1 or 2 substituents selected from fluoro, methyl, ethyl, amino, methylamino, dimethylamino, ethylamino, isopropylamino, hydroxy, oxo, aminomethyl, 1-aminoethyl, (isopropylamino)methyl, ureido, alanylamino, valylamino, fluoromethyl, difluoromethyl, trifluoromethyl, and 2,2,2-trifluoroacetyl;

or a tautomer, stereoisomer, a racemic or scalemic mixture of stereoisomers, a pharmaceutically acceptable salt, ester, solvate, or polymorph thereof.